Notably, CD30+ EVs bind to various DLBCL cell lines as well as to the FITC-labeled variant of the antibody-drug conjugate BV, thus potentially conferring the BV binding also to CD30– cells. This evidence concerns the gene TNFRSF8 and diffuse large B-cell lymphoma.